Endonovo Therapeutics, Inc. (ENDV)
Oxford Ledge is still expanding full research coverage of ENDV. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Endonovo develops wearable bioelectric medical devices for wound healing, pain relief, and treatment of various chronic diseases.
Source: 10-K (2022-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Entry into material agreement; Financial statements and exhibits 2024-01-03
- 10-Q/A Amended quarterly report 2023-12-29
- 10-Q Quarterly financial report (unaudited) 2023-12-29
- 8-K Entry into material agreement; Financial statements and exhibits 2023-12-04
- 8-K Other material event; Financial statements and exhibits 2023-10-12
Source: SEC EDGAR.
Annual results
5 years of annual figures for ENDV, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2022 | $135,355 | -$18.5M | — |
| 2021 | $73,105 | -$3.1M | — |
| 2020 | $165,796 | -$395,584 | — |
| 2019 | $310,164 | -$17.3M | — |
| 2018 | $83,263 | -$6.4M | — |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for ENDV. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ENDV in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.